Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16260385 | 1.00 | MEN1 (0.63) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL26382685 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL18768806 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL18768947 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL18768810 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL22619964 | 0.87 | CASP2 (0.67) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL20848160 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL19704868 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL18769027 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL19704886 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697680-B2 | Anti-GP73 antibodies and immunoconjugates | CUREAB GMBH (CH) | 2023-07-11 | — | — | US | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4026840-A1 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | Seagen Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162318-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-10981987-B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210095043-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10912813-B2 | Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates | SEAGEN INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3189082-B1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2020-08-19 | — | — | EP | disclosed |
| US-7855275-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-7750116-B1 | Antibody drug conjugate metabolites | SEATTLE GENETICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7723485-B2 | engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids; Cys engineered anti-MUC16 antibodies (Ab) containing a heavy chain sequence, conjugated with one or more drug moieties through a linker; diagnostic and therapeutic uses | GENENTECH, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100003766-A1 | screening cysteine engineered antibodies for thiol reactivity; using antibodies or antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor or cancer cells | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| EP-2100619-A1 | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders | Seattle Genetics, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | GENENTECH, INC. | 2008-12-18 | — | — | US | disclosed |
| US-7375078-B2 | Heterocyclic self-immolative linkers and conjugates | GENENTECH, INC. (US) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981987-B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | CD99, CD79B, CD47 | MEN1 1535/4885KMT2A 660/4885CASP2 3901/4885 |
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | MEN1 3021/4885KMT2A 1367/4885CASP2 3998/4885 |
| US-10912813-B2 | Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates | CD44, PABPC1, CD47 | MEN1 875/4885KMT2A 1377/4885CASP2 3263/4885 |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | MEN1 1668/4885KMT2A 3066/4885CASP2 4351/4885 |
| US-20210095043-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | MEN1 3113/4885KMT2A 2170/4885CASP2 4815/4885 |
| US-11697680-B2 | Anti-GP73 antibodies and immunoconjugates | CD74, CD63, IGSF11 | MEN1 3551/4885KMT2A 4145/4885CASP2 3394/4885 |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | MUC1, PDIA6, LNPEP | MEN1 1256/4885KMT2A 3446/4885CASP2 4555/4885 |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | ALB, LNPEP, CSTB | MEN1 3930/4885KMT2A 3830/4885CASP2 1984/4885 |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | MEN1 1535/4885KMT2A 660/4885CASP2 3901/4885 |
| US-20220162318-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | CD44, NECTIN4, H1-4 | MEN1 1354/4885KMT2A 747/4885CASP2 4023/4885 |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | MEN1 44/4885KMT2A 2858/4885CASP2 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.